Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.
about
Oncolytic virotherapy of canine and feline cancerTrial Watch:: Oncolytic viruses for cancer therapyOncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapyAntigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models.Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapyPreclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.On the potential of oncolytic virotherapy for the treatment of canine cancers.Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cellsUpdate on oncolytic viral therapy - targeting angiogenesisCanine brain tumours: a model for the human disease?State of play and clinical prospects of antibody gene transfer.Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.Establishment and characterization of a canine soft tissue sarcoma patient-derived xenograft model.Growth Factors and COX2 Expression in Canine Perivascular Wall Tumors.Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma
P2860
Q27008306-3CBF65EE-E8E1-40CD-B025-8B5C085B7DE8Q27021951-7CE0BDC5-CC52-458F-897D-CC60019AAA40Q33769835-EDE669CE-A5BF-45EB-A51E-FC35AAE20B96Q34005213-98603CEB-6219-41C4-96A6-B49D97D89517Q34142957-F088FFBC-3FDF-4BB9-A855-4EB8FAA07B2BQ34307934-18204C9B-2070-4F4B-ABA1-7C4258B43327Q35895339-4D318A96-8A95-47E0-AB25-E2848D3CD012Q36507259-CD3B26E2-071B-4071-9530-E2290769004FQ37031925-A11AB2D8-C531-47D3-8C20-39CB086F9E9DQ37156128-0EB15174-600E-4144-9C5C-A58FE7B0DDBBQ38128561-CB5DBE37-0074-4651-B39E-F2698643BF4FQ38491009-C5611A7A-9BB3-4501-97C5-AEC4FABEEC25Q38737706-4336558A-E77E-471B-BF9F-B6231B12880EQ41706553-AD88D478-EEFD-4E49-9D3B-9D5F94F00DFEQ53143903-64DFE8D2-64BA-4494-A55C-F1352D68E24CQ54283149-B7D78523-6073-4C37-BFCE-AD1621A24166Q59117175-C07BB680-764C-4ED6-9DE2-5A9A0DE541B7
P2860
Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.
@ast
Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.
@en
Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.
@nl
type
label
Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.
@ast
Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.
@en
Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.
@nl
prefLabel
Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.
@ast
Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.
@en
Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.
@nl
P2093
P2860
P1433
P1476
Virotherapy of canine tumors w ...... ti-VEGF single-chain antibody.
@en
P2093
Alexa Frentzen
Ingo Nolte
Ivaylo Gentschev
Marion Adelfinger
Michael Hess
Sandeep S Patil
Stephanie Weibel
Ulrike Donat
P2860
P304
P356
10.1371/JOURNAL.PONE.0047472
P407
P577
2012-10-16T00:00:00Z